What we claim is:

769746 Atsumi 8/27/85

A cephalosporin compound of the general formula (I)

$$R^{1} \xrightarrow{N} C-CON \xrightarrow{C-CON} S$$

$$OR_{2} OR_{2} CH=CH-A$$

$$CO_{2}R^{3}$$

$$(I)$$

wherein R¹ is an amino group or a protected amino group;
R² is a lower alkyl group, a carboxymethyl group or a
protected carboxymethyl group; R³ is a hydrogen atom,
a salt-forming cation or a carboxyl-protecting group;
A is an unsubstituted or substituted phenyl group, an
unsubstituted or substituted furyl group, an unsubstituted
or substituted thiazolyl group or an unsubstituted or
substituted 3-lower-alkylthiazolio group, and a pharmaceutically acceptable salt or ester of said cephalosporin
compound.

Jap. priority 9/7/84 = 7/18/85 544/22,27 514/202,206

72

2. A cephalosporin compound as claimed in Claim 1 which is of the general formula (Ia)

wherein R¹ is an amino group or a protected amino group, R² is a lower alkyl group, a carboxymethyl group or a protected carboxymethyl group, R³ is a hydrogen atom, a salt-forming cation or a carboxyl-protecting group, and Y is a hydrogen atom, a lower alkyl group, a lower alkoxyl group or a halogen atom.

a P N

3. A cephalosporin compound as claimed in Claim 1 which is of the general formula (Ib)

wherein R¹ is an amino group or a protected amino group, R² is a lower alkyl group, a carboxymethyl group or a protected carboxymethyl group, R³ is a hydrogen atom, a salt-forming cation or a carboxyl-protecting group, Z is a hydrogen atom, nitro group or a halogen atom.

A. A cephalosporin compound as claimed in claim 1 which is of the general formula (Ic)

wherein R¹ is an amino group or a protected amino group, R² is a lower alkyl group, a carboxymethyl group or a protected carboxymethyl group, and R³ is a hydrogen atom, a salt-forming cation or a carboxyl-protecting group.

33

A cephalosporin compound as claimed in claim 1 which is of the general formula (Id)

RB 10/30/86 T0760X

wherein R¹ is an amino group or a protected amino group, R² is a lower (C₁-C₆) alkyl group, a carboxymethyl group or a protected carboxymethyl group, R³ is a hydrogen atom a salt-forming cation or a carboxyl-protecting group, and R is a lower alkyl group.

44.

A cephalosporin compound as claimed in claim 1 which is of the general formula (Ie)

T0761X

wherein R^1 is an amino group or a protected amino group, R^2 is a lower $(C_1 - C_6)$ alkyl group, a carboxymethyl group or a protected carboxymethyl group, R^3 is a hydrogen atom, a salt-forming cation or a carboxyl-protecting group, and R^3 is a hydrogen atom or a halogen atom, and R^3 is a whole number of 1 or 2.

R

A cephalosporin compound as claimed in claim 1 which is of the general formula (If)

 $\begin{array}{c|c}
 & & \\
\hline
 &$

wherein R^1 is an amino group or a protected amino group, R^2 is a lower $(C_1 - C_6)$ alkyl group, a carboxymethyl group or a protected carboxymethyl group, and R^3 is a hydrogen atom, a salt-forming cation or a carboxyl-protecting group.

A compound as claimed in claims 1 to 7 in which R¹ is an amino group, R² is a methyl group or a carboxymethyl group, and R³ is sodium atom, benzhydryl group, p-methoxybenzyl group, diphenylmethyl group, pivaloyloxymethyl group or (5-methyl-2-oxo-1,3-dioxolene-4-yl)-methyl group.

9. A compound as claimed in Claim 1 which is selected from:-

7-[2-methoxyimino-2-(2-aminothiazo1-4-y1)acetamido]3-(2-phenylvinyl)-3-cephem-4-carboxylic acid (synisomer, trans-isomer, or syn-isomer, cis-isomer)
and its trifluoroacetate; and
7-[2-methoxyimino-2-(2-aminothiazo1-4-y1)acetamido]3-[2-(o-fluorophenyl)vinyl)-3-cephen-4-carboxylic
acid (syn-isomer, trans-isomer, or syn-isomer, cisisomer) and its trifluoroacetate.

10. A compound as claimed/in Claim 1 which is selected from:-

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido]3-[2-(2-furyl)vinyl]-3-cephem-4-carboxylic acid
(syn-isomer, trans-isomer, or syn-isomer, cis-isomer)
and its sodium salt; and
7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido]3-[2-(5-nitro-2-furyl)vinyl]-3-cephem-4-carboxylic
acid (syn-isomer, trans-isomer, or syn-isomer, cisisomer) and its sodium salt.



A compound as claimed in claim 1 which is selected from the group consisting of

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido] 3-[2-(thiazol-2-yl)vinyl]-3-cephem-4-carboxylic acid (syn-isomer, trans-isomer, or syn-isomer, cis-isomer);

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido]3-[2-(thiazol-4-yl)vinyl]-3-cephem-4-carboxylic acid
(syn-isomer, cis-isomer) and its sodium salt and its
pivaloyloxymethyl ester; and

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido]
3-[2-(thiazol-5-yl)vinyl]-3-cephem-4-carboxylic acid
(xyn-isomer, cis-isomer), its sodium salt, and its
pivaloyloxymethyl ester.

2

4 8

A compound as claimed in claim I which is selected from the group Consisting of

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido]3-[2-(4-methylthiazol-5-yl)vinyl]-3-cepehm-4-carboxylic
acid (cyn-isomer, trans isomer, or cyn-isomer, cisisomer), its sodium salt, its trifluoroacetate, its
pivaloyloxymethyl ester, and its (5-methyl-2-oxo-1,3dioxolene-4-yl)-methyl ester;

Po

7-[2-carboxymethoxyimino-2-(2-aminothiazol-4-yl)

b acetamido]-3-[2-(4-methylthiazol-5-yl)vinyl]-3-cephem

4-carboxylic acid (syn-isomer, trans-isomer, or syn)

b cladbtion saltwith trifluoroacetate,

isomer, cis-isomer) and its trifluoroacetate,

PU

7-[2-t-butoxycarbonylmethoxyimino-2-(2-tritylamino
thiazol-4-yl)acetamido]-3-[2-(4-methylthiazol-5-yl)

vinyl]-3-cephem-4-carboxylic acid (syn-isomer,

trans-isomer, or syn-isomer, cis-isomer); and

Po

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido]
3-[2-(2-methylthiazol-5-yl)vinyl]-3-cephem-4-carboxylic
acid (syn-isomer, trans-isomer, or syn-isomer, cist
licit addition and with trifluoreacetic acid
isomer), its sodium salt, its trifluoreacetate, and
its (5-methyl-2-oxo-1,3-dioxolene-4-yl)-methyl ester.

a

79

A compound as claimed in claimed in which is selected from the group consisting of


7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido] 3-[2-(4-chlorothiazol-5-yl)vinyl]-3-cephem-4-carboxylic acid (syn-isomer, cis-isomer), its sodium salt and its pivaloyloxymethyl ester; and

 \mathcal{C} 7-[2-methoxyimino-2-(2-amino-thiazol-4-yl)acetamido] 3-[2-(2,4-dichlorothiazol-5-yl)vinyl]-3-cephem-4carboxylic acid (syn-isomer, cis-isomer), its sodium salt and its pivaloyloxymethyl ester.

A compound as claimed in claim 1 which is 7-[2]methoxyimino-2-(2-aminothiazol-4-yl)acetamido]-3-[2-(3,4 \oplus dimethyl-5-thiazolio)vinyl]-3-cephem-4-carboxylic acid addition salt with trifluorioantic acid

7-[2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido] 3-[2-(4-methylthiazol-5-yl)vinyl]-3-cephem-4-carboxylic acid (syn-isomer, cis-isomer) sodium salt.

7-[2-methoxyimino-2-(2-aminothiazol&-4-yl)acetamido] 😂 3-[2-(4-methylthazole-5-yl)vinyl]-3-cephem-4-carboxylic acid (syn-isomer, cis-isomer) pivaloyloxymethyl ester.



wherein R¹ is an amino group or a protected amino group, R² is a lower alkyl group, a carboxymethyl group or a protected carboxymethyl group, R³ is a hydrogen atom, a salt-forming cation of a carboxyl-protecting group, and A is an unsubstituted or substituted phenyl group, an unsubstituted or substituted furyl group or an unsubstituted or substituted thiazolyl group or an unsubstituted or substituted thiazolyl group or an unsubstituted or substituted 3-lower-alkylthiazolio group, characterized in that the process comprises reacting a 7-aminocephalosporanic acid compound of the general formula (II)

$$H_2N$$
 $CH=CH-A$
 CO_2R^3

wherein \mathbb{R}^3 and A are as defined above, or a functional equivalent thereof (including a reactive derivative at the amino group of the compound of the formula (II) and a salt

of the compound of the formula (II)), with a 2-(2-amino-thiazol-4-yl)-2-alkoxyimino-acetic acid compound of the formula (III)

$$R^{1}$$
 S
 $C-CO_{2}H$
 OR^{2}
 OR^{2}

wherein R¹ and R² are as defined above, or a functional equivalent thereof (including a reactive acid derivative of the compound of the formula (III)) in an unreactive solvent at a temperature of not higher than the boiling temperature of the solvent used, to produce the compound of the formula (I), and then, if desired, where the product compound of the formula (I) as produced is such one as shown by the formula (I")

$$R^{1}$$
 S
 $C-CONH$
 OR
 $CH=CH$
 N
 S
 $CH=CH$
 S
 R^{5}
 S
 R^{4}

wherein R^1 , R^2 and R^3 are as defined above, and R^4 and R^5 are the same or different and each are a hydrogen atom, a lower alkyl group or a halogen atom, alkylating the 3-nitrogen/atom of the thiazolyl group of the compound

of the formula (I") by reacting with an alkyl halide of the formula RX wherein R is a lower alkyl group and X is a halogen atom, or a mono- or di-lower-alkyl sulfate or a lower alkyl lower-alkanesulfonate, to produce the compound of the formula (I"')

wherein R¹, R², R³, R⁴ and R⁵ are as defined above and R is corresponding to the lower alkyl group of the alkyl halide or the mono- or di-lower-alkyl sulfate or the lower alkyl lower-alkanesulfonate employed, and further, if desired, removing the remaining amino-protecting group and the remaining carboxyl-protecting group from the product compound of the formula (I) or of the formula (I"').

A pharmaceutical, antibacterial composition which comprises an antibacterially effective amount of the compound of the formula (I) as defined in claim 1 or the compound of the formula (Ia) to (If) as defined in claims to for a pharmaceutically acceptable salt or ester thereof, as the active ingredient, in combination with a pharmaceutically acceptable carrier for the active ingredient.

هي ا

918CC